<DOC>
	<DOCNO>NCT01463696</DOCNO>
	<brief_summary>This study do evaluate safety pharmacokinetic profile MK-8242 active metabolite ( M16 ) participant advance solid tumor . In Part 1 study , study drug dose escalate determine maximum tolerate dose ( MTD ) . In Part 2 study , MTD confirm recommended Phase 2 dose ( RPTD ) establish ; effect MK-8242 liposarcoma tumor type also evaluate .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics MK-8242 Participants With Advanced Solid Tumors ( P07650 )</brief_title>
	<detailed_description>Participants consider complete study Cycle 12 . Amendment 4 ( 14 April 2015 ) do allow participant active treatment time study close enrollment continue study treatment beyond Cycle 12 derive clinical benefit , Investigator 's discretion .</detailed_description>
	<criteria>Inclusion criterion : Histologically confirm advanced solid tumor effective standard therapy option Willing provide tumor tissue p53 wild type gene analysis Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Adequate organ function Female participant male participant partner childbearing potential must agree abstain sexual intercourse use acceptable method contraception study 90 day follow last dose study drug At least one measurable lesion In Part 2 , participant liposarcoma must confirm welldifferentiated dedifferentiated histology Exclusion criterion : Known treat untreated leptomeningeal metastasis , metastatic central nervous system disease History recent myocardial infarction ( within past year ) ; unstable uncontrolled angina , New York Heart Association ( NYHA ) Class III IV congestive heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant electrocardiogram ( ECG ) abnormality Uncontrolled active infection optimal systemic treatment Clinically significant hepatitis hepatitis C antibody positive , hepatitis B surface antigen positive , human immunodeficiency virus ( HIV ) seropositive Persistent , unresolved common terminology criterion adverse event ( CTCAE v4.0 ) ≥Grade 2 drugrelated toxicity associate previous treatment except alopecia Radiation therapy locoregional therapy within 2 week prior study Use moderate strong cytochrome P450 inhibitor inducer within 1 week prior study Chemotherapy investigational drug ( ) within 4 week prior study Known hypersensitivity MK8242 component Nursing , pregnant , intention become pregnant study Initiating bisphosphonate therapy adjust bisphosphonate dose regimen within 30 day Cycle 1 Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>